BriaCell Expands Phase 3 Breast Cancer Trial to Memorial Sloan Kettering
Event summary
- Memorial Sloan Kettering Cancer Center (MSK) joins BriaCell’s Phase 3 trial for metastatic breast cancer, expanding patient access.
- Trial now includes over 80 clinical sites across 15 states, with Bria-IMT plus an immune checkpoint inhibitor as the treatment regimen.
- Primary endpoint is overall survival (OS), with interim analysis planned after 144 deaths occur.
- Bria-IMT regimen received FDA Fast Track designation, and Phase 2 data showed positive survival outcomes in a similar patient population.
The big picture
BriaCell’s expansion into MSK signals a strategic push to validate its immunotherapy approach in a high-profile setting, aligning with broader industry trends toward combination therapies in oncology. The Phase 3 trial’s progress will be critical in determining whether Bria-IMT can carve out a niche in a competitive market dominated by established treatments.
What we're watching
- Trial Execution
- Whether the addition of MSK accelerates patient enrollment and data readouts in the Phase 3 study.
- Regulatory Pathway
- How the FDA Fast Track designation may influence the timing and conditions of a potential approval.
- Competitive Positioning
- The pace at which BriaCell can differentiate Bria-IMT in a crowded metastatic breast cancer treatment landscape.
Related topics